Evidence map›Paper›PMID 39256842›Full record

ArticleMalaria journal2024

CUREMA project: a further step towards malaria elimination among hard-to-reach and mobile populations.

Alice Sanna, Yann Lambert, Irene Jimeno Maroto, Muriel Suzanne Galindo, Lorraine Plessis, Teddy Bardon, Carlotta Carboni, Jane Bordalo, Helene Hiwat, Hedley Cairo and 7 more

Abstract read
In one paragraph

Article in Malaria journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Alice SannaFrench West Indies-French Guiana Center for Clinical Investigation (CIC Inserm 1424), Department of Research, Innovation, and Public Health, Cayenne Hospital, Cayenne, French Guiana, France. a.sanna33@gmail.com.
Yann LambertFrench West Indies-French Guiana Center for Clinical Investigation (CIC Inserm 1424), Department of Research, Innovation, and Public Health, Cayenne Hospital, Cayenne, French Guiana, France.
Irene Jimeno MarotoFrench West Indies-French Guiana Center for Clinical Investigation (CIC Inserm 1424), Department of Research, Innovation, and Public Health, Cayenne Hospital, Cayenne, French Guiana, France.
Muriel Suzanne GalindoFrench West Indies-French Guiana Center for Clinical Investigation (CIC Inserm 1424), Department of Research, Innovation, and Public Health, Cayenne Hospital, Cayenne, French Guiana, France.
Lorraine PlessisFrench West Indies-French Guiana Center for Clinical Investigation (CIC Inserm 1424), Department of Research, Innovation, and Public Health, Cayenne Hospital, Cayenne, French Guiana, France.
Teddy BardonFrench West Indies-French Guiana Center for Clinical Investigation (CIC Inserm 1424), Department of Research, Innovation, and Public Health, Cayenne Hospital, Cayenne, French Guiana, France.
Carlotta CarboniFrench West Indies-French Guiana Center for Clinical Investigation (CIC Inserm 1424), Department of Research, Innovation, and Public Health, Cayenne Hospital, Cayenne, French Guiana, France.
Jane BordaloAssociação Desenvolvimento, Prevenção, Acompanhamento e Cooperação de Fronteiras (DPAC), Oiapoque, Brazil.
Helene HiwatNational Malaria Programme, Ministry of Health, Paramaribo, Suriname.
Hedley CairoNational Malaria Programme, Ministry of Health, Paramaribo, Suriname.
Lise MussetLaboratoire de Parasitologie, Institut Pasteur de la Guyane, Centre National de Référence du Paludisme, Cayenne, French Guiana, France.
Yassamine LazrekLaboratoire de Parasitologie, Institut Pasteur de la Guyane, Centre National de Référence du Paludisme, Cayenne, French Guiana, France.
Stéphane PelleauInfectious Disease Epidemiology and Analytics, Institut Pasteur, Université Paris Cité, Paris, France.
Michael WhiteInfectious Disease Epidemiology and Analytics, Institut Pasteur, Université Paris Cité, Paris, France.
Martha Suárez MutisLaboratory of Parasitic Diseases, Graduate Program in Tropical Medicine, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro, Brazil.
Stephen VredenFoundation for the Advancement of Scientific Research in Suriname (SWOS), Paramaribo, Suriname.
Maylis DouineFrench West Indies-French Guiana Center for Clinical Investigation (CIC Inserm 1424), Department of Research, Innovation, and Public Health, Cayenne Hospital, Cayenne, French Guiana, France.

Funding

FEDER - Programme de Coopération Interreg Amazonie SYNERGIE 7128 and 8754
6 · The paper itself

Abstract

backgroundIn most countries engaged on the last mile towards malaria elimination, residual transmission mainly persists among vulnerable populations represented by isolated and mobile (often cross-border) communities. These populations are sometimes involved in informal or even illegal activities. In regions with Plasmodium vivax transmission, the specific biology of this parasite poses additional difficulties related to the need for a radical treatment against hypnozoites to prevent relapses. Among hard-to-reach communities, case management, a pillar of elimination strategy, is deficient: acute malaria attacks often occur in remote areas, where there is limited access to care, and drugs acquired outside formal healthcare are often inadequately used for treatment, which typically does not include radical treatment against P. vivax. For these reasons, P. vivax circulation among these communities represents one of the main challenges for malaria elimination in many non-African countries. The objective of this article is to describe the protocol of the CUREMA study, which aims to meet the challenge of targeting malaria in hard-to-reach populations with a focus on P. vivax.

resultsCUREMA is a multi-centre, international public health intervention research project. The study population is represented by persons involved in artisanal and small-scale gold mining who are active and mobile in the Guiana Shield, deep inside the Amazon Forest. The CUREMA project includes a complex intervention composed of a package of actions: (1) health education activities; (2) targeted administration of treatment against P. vivax after screening against G6PD deficiency to asymptomatic persons considered at risk of silently carrying the parasite; (3) distribution of a self-testing and self-treatment kit (malakit) associated with user training for self-management of malaria symptoms occurring while in extreme isolation. These actions are offered by community health workers at settlements and neighbourhoods (often cross-border) that represent transit and logistic bases of gold miners. The study relies on hybrid design, aiming to evaluate both the effectiveness of the intervention on malaria transmission with a pre/post quasi-experimental design, and its implementation with a mixed methods approach.

conclusionsThe purpose of this study is to experiment an intervention that addresses both Plasmodium falciparum and P. vivax malaria elimination in a mobile and isolated population and to produce results that can be transferred to many contexts facing the same challenges around the world.

Indexed as

Disease EradicationMalaria, VivaxAdolescentAdultAntimalarialsChildFemaleHumansMaleMiddle AgedPlasmodium vivaxYoung AdultAntimalarialsCross-borderEliminationHard-to-reach populationMalariaMobilityPlasmodium vivaxPublic health interventionRadical cureResearch protocol

Identifiers

PMID39256842
PMCPMC11385508

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.